| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 |
|---|---|---|---|---|---|---|---|---|---|
Revenues: | |||||||||
Product sales | |||||||||
4,063 | 0 | - | - | - | - | - | - | - | - |
Lease income | |||||||||
68 | 0 | - | - | - | - | - | - | - | - |
Product sales | |||||||||
- | - | - | 0 | 47 | 23 | 0 | - | - | - |
Revenues Total | |||||||||
- | - | - | - | 47 | 23 | 0 | - | - | - |
Royalties | |||||||||
- | - | - | - | - | - | - | 669 | 1,940 | 3,448 |
Other | |||||||||
- | - | - | - | - | - | - | - | - | 244 |
Total revenues | |||||||||
4,131 | 0 | 0 | 0 | - | - | - | 669 | 1,940 | 3,693 |
Costs and expenses: | |||||||||
Costs of revenues | |||||||||
3,935 | 0 | - | - | - | - | - | - | - | - |
Cost of product sales | |||||||||
- | - | - | - | 6 | 7 | 0 | - | - | - |
Research and development | |||||||||
9,748 | 8,507 | 7,595 | 4,645 | 4,075 | 2,765 | 2,677 | 2,375 | 3,457 | 4,829 |
General and administrative | |||||||||
27,336 | 17,997 | 3,156 | 4,775 | 3,118 | 3,756 | 3,063 | 2,797 | 3,051 | 3,397 |
Selling and marketing | |||||||||
3,103 | 0 | - | - | - | - | - | - | - | - |
Acquired in-process research and development | |||||||||
6,967 | 687 | - | - | - | - | - | - | - | - |
Acquired in-process research and development | |||||||||
- | - | 0 | - | - | 19,681 | 0 | - | - | 3,000 |
Total cost and expenses | |||||||||
51,089 | 27,191 | 10,751 | 9,420 | 7,200 | 26,211 | 5,740 | 5,173 | 6,508 | 11,227 |
Loss from operations | |||||||||
-46,958 | -27,191 | - | - | - | - | - | - | - | - |
Non-operating income/(expense): | |||||||||
Interest income, net | |||||||||
1,062 | 40 | 1 | -26 | -81 | -26 | 1 | -10,041 | - | - |
Foreign exchange gains | |||||||||
817 | 0 | - | - | - | - | - | - | - | - |
Change in fair value of investment in equity securities | |||||||||
288 | 320 | 0 | - | - | - | - | - | - | - |
Other income | |||||||||
5 | 0 | - | - | - | - | - | - | - | - |
Net loss | |||||||||
-45,362 | -27,471 | - | - | - | - | - | - | - | - |
Less: (loss)/ income attributable to redeemable noncontrolling interest | |||||||||
-395 | 0 | - | - | - | - | - | - | - | - |
Accretion to redeemable noncontrolling interest redemption value | |||||||||
1,065 | 0 | - | - | - | - | - | - | - | - |
Change in fair value of contingent rights | |||||||||
- | - | 19 | 6 | -27 | -11 | 0 | - | - | - |
Interest (income) expense | |||||||||
- | - | - | - | - | - | - | - | 0 | 540 |
Other income (expense) | |||||||||
- | - | - | - | - | - | - | - | 9 | -26 |
Net loss attributable to CASI Pharmaceuticals, Inc. | |||||||||
-46,032 | -27,471 | -10,770 | -9,453 | -7,206 | -26,202 | -5,738 | -14,545 | -4,558 | -8,101 |
Dividends on Series A convertible preferred stock | |||||||||
- | - | - | - | - | - | - | 335 | 1,005 | 1,005 |
Net loss attributable to common shareholders | |||||||||
- | - | - | - | - | - | - | -14,880 | -5,563 | -9,106 |
Net loss per share (basic and diluted) (in dollars per share) | |||||||||
-0.48 | -0.32 | -0.18 | -0.17 | -0.22 | -0.92 | -0.22 | -0.78 | -0.47 | -0.94 |
Weighted average number of common shares outstanding (basic and diluted) | |||||||||
95,948 | 84,752 | 61,513 | 55,869 | 32,445 | 28,595 | 26,125 | 19,055 | 11,781 | - |
Comprehensive loss: | |||||||||
Net loss | |||||||||
-45,362 | -27,471 | - | - | - | - | - | - | - | - |
Net loss | |||||||||
-46,032 | -27,471 | -10,770 | - | - | - | - | - | - | - |
Foreign currency translation adjustment | |||||||||
-1,501 | -1,227 | 0 | - | - | - | - | - | - | - |
Total comprehensive loss | |||||||||
-46,863 | -28,698 | - | - | - | - | - | - | - | - |
Less: Comprehensive (loss)/income attributable to redeemable noncontrolling interest | |||||||||
-395 | 0 | - | - | - | - | - | - | - | - |
Comprehensive loss attributable to common stockholders | |||||||||
-46,468 | -28,698 | -10,770 | - | - | - | - | - | - | - |
Weighted average number of shares outstanding (basic and diluted) | |||||||||
- | - | - | - | - | - | - | - | - | 9,678 |
Product sales [Member] | |||||||||
Revenues Total | |||||||||
- | - | 0 | - | - | - | - | - | - | - |